13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05740722 (ClinicalTrials.gov) | March 1, 2023 | 30/1/2023 | Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis | Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis: A Randomised Controlled Trial: The NORSEMAN Study | Multiple Sclerosis;Progressive Multiple Sclerosis | Dietary Supplement: Nicotinamid riboside;Dietary Supplement: Placebo | Haukeland University Hospital | NULL | Not yet recruiting | 18 Years | 65 Years | All | 300 | Phase 2 | Norway |